Abstract
To compare the effect of fixed-dose trandolapril-verapamil (FDTV) with that of trandolapril on proteinuria in normotensive, type 2 diabetic patients. A total of 60 normotensive, type 2 diabetic patients with 24-h proteinuria >300 mg were randomly assigned to two groups for open-label treatment. One group received 2 mg trandolapril/180 mg verapamil FDTV once daily; the other group received 2 mg trandolapril once daily. Study drugs were administered for 6 months in both groups. Creatinine clearance and 24-h urinary protein excretion were measured at the beginning and the end of the study. Patients were evaluated monthly for blood pressure, fasting blood glucose level, heart rate, and adverse events. Statistical analysis was performed using ANOVA. Both groups experienced a statistically significant (P < 0.005) mean decrease in mean proteinuria from baseline: FDTV ([mean +/- SD] 1200 +/- 200 to 540 +/- 79 mg; P < 0.001) and trandolapril (1,105 +/- 212 to 750.9 +/- 134 mg; P < 0.005). A significantly greater reduction from baseline in proteinuria was observed in the FDTV group compared with the trandolapril group. Patients who received trandolapril experienced a statistically significant (P < 0.05) decrease in mean creatinine cleara...Continue Reading
References
Jan 1, 1997·Drugs·T J Rabelink, H A Koomans
Jul 1, 1997·Diabetes Care·M W Steffes
Apr 1, 1997·The American Journal of Medicine·M E Molitch
Oct 10, 1998·Kidney International·G L BakrisF G McMahon
Dec 19, 2001·Annals of Internal Medicine·N M Kaplan
Jan 5, 2002·Journal of Human Hypertension·R FernándezUNKNOWN TRAVEND Study Group
Mar 8, 2002·Hypertension·Joon-Keun ParkHermann Haller
Oct 29, 2002·Diabetes Care·Ferdinando C SassoDomenico Cozzolino
Jan 28, 2003·Diabetes Care·Dan R BerlowitzBoris Kader
May 27, 2003·Diabetes Care·Jeremy W TomlinsonColin F Close
May 27, 2003·Diabetes Care·Kathrine J CraigAled O Phillips
Jun 5, 2003·Journal of Hypertension·UNKNOWN European Society of Hypertension-European Society of Cardiology Guidelines Committee
Citations
May 30, 2009·Vascular Health and Risk Management·Gianpaolo ReboldiPaolo Verdecchia
May 30, 2007·Clinical Drug Investigation·Alberto Francisco Rubio-GuerraLuz María Ramos-Brizuela
Jan 15, 2010·Srpski arhiv za celokupno lekarstvo·Nada Dimković, Sinisa Dimković
Dec 3, 2014·Primary Care·Kelly MercierJason Biederman
Nov 8, 2011·Hospital Practice·Kenta OkadaShun Ishibashi
Mar 20, 2008·Renal Failure·Nicolás Roberto Robles
Oct 25, 2006·Clinical and Experimental Hypertension : CHE·Alberto Francisco Rubio-GuerraBruno Alfonso Escalante-Acosta
Oct 16, 2008·Clinical and Experimental Hypertension : CHE·Alberto Francisco Rubio-GuerraBruno Alfonso Escalante-Acosta
Apr 29, 2005·Diabetes/metabolism Research and Reviews
Nov 10, 2006·Diabetes/metabolism Research and Reviews·György Jermendy, Piero Ruggenenti
Feb 14, 2006·The Journal of Clinical Hypertension·Sara Giunti, Mark Cooper
Apr 11, 2019·The Annals of Pharmacotherapy·Taylor D SteuberMiranda R Andrus
Jun 7, 2019·Acta Diabetologica·Carla CarnovaleEmilio Clementi
Oct 17, 2018·International Urology and Nephrology·Punnaka PongpanichPaweena Susantitaphong